Fluidigm Corporation
has announced the availability of new assays and primers optimized for the
company's integrated fluidic circuit technology. Fluidigm Assays and
Target-specific Primers will provide customers with significantly lower costs
than today's standard solutions, at volumes appropriate for microfluidics, and
flexible chemistries so that customers can easily create highly multiplexed
panels using off-the-shelf and custom content focused on their particular
research area. As part of the program, Fluidigm will provide the assay primer
locus sequences with every order.
The products are being marketed as DELTAgene
TM Assays (gene expression),
SNPtype
TM Assays (SNP genotyping), and Access Array
TM Target-specific Primers
(target enrichment for next-generation sequencing).
"Due to our chemistry
choice, our assays are priced substantially lower than labeled probe-based
methods, so users can purchase hundreds of assays at a cost that is
affordable. It has long been known that there are substantial benefits
for researchers exploring multiple targets. In gene expression and genotyping
studies, more targets provide better information and higher quality end
results. The key was being able to achieve these results at a reasonable cost
and rapid throughput. Fluidigm Assays provide that capability," said Gajus
Worthington, president and chief executive officer, Fluidigm. "In
addition, our assay customers will receive the assay locus sequence from
us on every order which will make it easier for the results to be MIQE compliant.
This is something researchers have long sought and Fluidigm is committed to
making our customers successful."
MIQE (minimum information for publication of quantitative real-time PCR
experiments) was designed to provide commonsense guidelines for enhancing the
reproducibility and transparency of quantitative real-time PCR assays.
The new DELTAgene Assays for gene expression can be custom designed to any
reference sequence. In addition, Fluidigm has a catalog of biologically grouped
quantitative PCR assays that researchers can customize into panels. Fluidigm
SNPtype Assays offer a low-cost SNP genotyping solution. These assays are made
on-demand and are ready to meet high-throughput needs for a wide range of
agricultural applications and confirmation of next-generation sequencing
results. The new range of Fluiidgm Access Array Target-specific Primers provide
an easy way for customers to generate sequencer ready amplicons for
next-generation sequencing. Currently, Fluidigm offers custom PCR-based primer design
for human and mouse targeted resequencing.
Fluidigm provides sufficient volume of assay and primer solution to run
hundreds of Fluidigm chips at costs substantially lower than traditional
competitors offer. The company has simple-to-use protocols that save customers
time and effort. This allows researchers to spend less time on assay
development and more time gathering results and publishing quickly.
Fluidigm (NASDAQ:FLDM) develops, manufactures and markets microfluidic systems
for growth markets in the life science and agricultural biotechnology, or
Ag-Bio, industries. Fluidigm's proprietary microfluidic systems consist of
instruments and consumables, including chips and reagents. These systems are
designed to significantly simplify experimental workflow, increase throughput
and reduce costs, while providing the excellent data quality demanded by
customers. Fluidigm actively markets three microfluidic systems, including
eight different commercial chips, to leading pharmaceutical and biotechnology companies,
academic institutions and Ag-Bio companies.
For more information, please visit
www.fluidigm.com.
*
Fluidigm, the Fluidigm logo, BioMark, Access Array, Dynamic Array, Digital
Array, FC1, TOPAZ, NanoFlex DELTAgene and SNPtype are trademarks or registered
trademarks of Fluidigm Corporation